Malaria is a great concern for global health and accounts for a large amount of morbidity and
mortality, particularly in Africa, with sub-Saharan Africa carrying the greatest burden of the …

Background The spread of resistance to chloroquine (CQ) led to its withdrawal from use in
most countries in sub-Saharan Africa in the 1990s. In Malawi, this withdrawal was followed …

The emergence of Plasmodium falciparum resistance to widely used antimalarial drugs such
as chloroquine (CQ) has made malaria control and treatment much more difficult. This is …

Faced with intense levels of chloroquine (CQ) resistance in Plasmodium falciparum malaria,
Rwanda replaced CQ with amodiaquine (AQ)+ sulfadoxine-pyrimethamine (SP) in 2001 …

Drug‐resistant parasites repeatedly arise as a result of widespread use of antimalarial drugs
and have contributed significantly to the failure to control and eradicate malaria throughout …

Chloroquine (CQ) resistance was first documented in Uganda in 1988. Subsequent
surveillance of antimalarial drug resistance, conducted by the Ugandan Ministry of Health …

Background As a result of widespread chloroquine and sulphadoxine-pyrimethamine (SP)
resistance, 90% of sub-Saharan African countries had adopted policies of artemisinin-based …

Malaria continues to be a leading cause of death in the tropics, taking the heaviest toll on
children in Africa, where drug resistant Plasmodium falciparum has led to rising malaria …

Background Chloroquine, a previous highly efficacious, easy to use and affordable anti-
malarial agent was withdrawn from malaria endemic regions due to high levels of …

Despite considerable efforts, malaria is still one of the most devastating infectious diseases
in the tropics. The rapid spread of antimalarial drug resistance currently compounds this …